Glenmark Pharma to study potential COVID-19 drug combination

Tuesday, 26 May 2020Newsdesk

In India, Glenmark Pharmaceuticals Ltd said on Tuesday it will begin a new clinical trial to test a combination of two anti-viral drugs, favipiravir and umifenovir, as a potential COVID-19 treatment.

New Delhi, 26 May 2020

As per news report of Reuters, the study will look to enroll 158 hospitalized patients suffering from moderate COVID-19 infections in India, the company said.

Drugmakers across the world have been rushing to develop a treatment or vaccine for the fast-spreading coronavirus. In India, now among the 10 most affected nations, the death toll from COVID-19 reached 4,167 on Tuesday.

Source -reuters.com